Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia

Figures & data

Figure 1 Forest plot of change in average daily pain score from baseline, placebo subtracted, last-observation-carried-forward methodology.

Abbreviations: G-GR, once-daily gastroretentive gabapentin; CI, confidence interval.

Figure 2 Patient disposition, safety population.

Abbreviation: G-GR, once-daily gabapentin.

Table 1 Patient disposition and baseline characteristics of the safety population

	G-GR (n = 359)	Placebo (n = 364)	Total (n = 723)
Age, years
Mean (SD)	66.3 (12.9)	65.9 (11.8)	66.1 (12.4)
Range	25–89	21–87	21–89
Sex, n (%)
Female	213 (59.3)	202 (55.5)	415 (57.4)
Male	146 (40.7)	162 (44.5)	308 (42.6)
Race, n (%)
Caucasian	313 (87.2)	327 (89.8)	640 (88.5)
Black	17 (4.7)	10 (2.7)	27 (3.7)
Hispanic	22 (6.1)	22 (6.0)	44 (6.1)
Other	7 (1.9)	5 (1.4)	12 (1.7)
ADP score, baseline
Mean (SD)	6.5 (1.4)	6.6 (1.4)	6.5 (1.4)
Range	4.0–10	4.0–10	4.0–10

Note: Includes patients initially randomized to receive asymmetric divided dose of G-GR in one study (asymmetric divided dose group not included in this analysis).

Abbreviations: ADP, average daily pain; G-GR, once-daily gastroretentive gabapentin; SD, standard deviation.

Figure 3 Subgroup analyses, adverse events (with >3% incidence in patients in G-GR cohort).

Abbreviation: G-GR, once-daily gabapentin.